Publication|Articles|August 6, 2023
- Pharmaceutical Executive: August 2023
- Volume 43
- Issue 8
Pharmaceutical Executive, August 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive August 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 2 years ago
Executive Roundtable: Innovations in Global Pharma Labelingover 2 years ago
A Fierce Focus On Unmet Needover 2 years ago
Pharma's ESG Equation: Materiality and Strategy are Keyover 2 years ago
Bridging the Divide: Medical's Omnichannel Momentumover 2 years ago
AI and Drug 'Re-Innovation'over 2 years ago
More Evidence is Pointing to Potential Swing for Biotechover 2 years ago
2023 Proxy Season: Record Proposals, Sliding Supportover 2 years ago
Do Findings Point to a Tarnished COVID Victory for Europe?Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases
2
Pfizer Enters Exclusive Collaboration and License Agreement with Yao Pharma for Oral Small-Molecule GLP-1 Agonists
3
Carvykti Displays Sustained Remissions in Early Use for Relapsed or Refractory Multiple Myeloma
4
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
5
